All In Biotech

Drug Trial Radar · NCT05450432

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 13, 2022

Primary completion

May 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Foundation for Suicide Prevention
First posted
Jul 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit. Eligible patients who provided informed consent will be enrolled in the study that will include a eight IV ketamine treatments, 13 esketamine treatment visits, seven long assessment visits, five short assessment visits, and daily surveys. The study will examine the feasibility, tolerability, and efficacy of repeated IV ketamine followed by esketamine, as well as predictors of treatment response.

Conditions

  • Major Depressive Disorder

Interventions

  • KetamineDrug

    Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.

  • EsketamineDrug

    After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility - RetentionTime frame: 24 weeks
  2. Feasibility - Drop-out RatesTime frame: 24 weeks
  3. Tolerability - Cognitive Function and Side EffectsTime frame: Weeks 0, 1, 2, 3, 4, 8, and 12-24
  4. Tolerability - Dosage of TreatmentTime frame: Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24
  5. Tolerability - Frequency of TreatmentTime frame: Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.